Allogene Therapeutics (ALLO) vs Arvinas (ARVN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Allogene Therapeutics (ALLO) has outperformed Arvinas (ARVN) over the past year, gaining 5.9% versus a loss of 19.9%. Over five years, ARVN leads with a -91.2% price change compared with -91.3% for ALLO. Allogene Therapeutics is the larger company by market cap ($494.1 million vs $480.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLO | ARVN |
|---|---|---|
| Share price | $1.43 | $7.45 |
| Market cap | $494.05M | $480.68M |
| 1-day change | -2.05% | +1.92% |
| YTD return | +4.38% | -37.18% |
| 1-year return | +5.93% | -19.89% |
| 5-year return | -91.32% | -91.25% |
| P/E ratio (TTM) | — | 28.65 |
| EPS (TTM) | $-0.66 | $0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.46 | $14.51 |
| 52-week low | $1.04 | $6.97 |
| Distance from 52-week high | -67.94% | -48.66% |
| Analyst consensus | none | buy |
| Avg. price target upside | +529.37% | +86.98% |
| Average volume | 5.78M | 779.91K |
| Shares outstanding | 345.49M | 64.52M |
| Employees | 150 | 246 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALLO has outperformed ARVN by 25.8 percentage points over the past year.
About Allogene Therapeutics
ALLO stock →Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 150 employees
About Arvinas
ARVN stock →Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Health Care · Biotechnology: Pharmaceutical Preparations · 246 employees
ALLO vs ARVN FAQ
Which is bigger, Allogene Therapeutics or Arvinas?
Allogene Therapeutics (ALLO) is larger, with a market capitalization of $494.05M compared with $480.68M for Arvinas (ARVN).
Which stock has performed better over the past year, ALLO or ARVN?
ALLO returned +5.93% over the past 12 months, compared with -19.89% for ARVN (price return, excluding dividends). Past performance does not predict future results.
Are Allogene Therapeutics and Arvinas in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Allogene Therapeutics and Biotechnology: Pharmaceutical Preparations for Arvinas.